On Monday, Alnylam Pharmaceuticals earned a positive adjustment to its Relative Strength (RS) Rating, from 62 to 75.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks compares to the rest of the market.
History shows that the best-performing stocks typically have an RS Rating north of 80 as they begin their largest price moves. See if Alnylam Pharmaceuticals can continue to rebound and hit that benchmark.
Looking For The Best Stocks To Buy And Watch? Start Here
Alnylam Pharmaceuticals is working on the right side of a double bottom with a 199.98 buy point. See if the stock can break out in volume at least 40% above average. Keep in mind the weakness of the group and the overall market. Not to mention current headlines.
While EPS growth fell in the prior quarter from 0% to -5%, revenue rose 58%, up from 49% in the previous report.
Alnylam Pharmaceuticals holds the No. 52 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
